Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT [Phase 1]
Phase 1 clinical trial update on DLI-X as a prophylactic and therapeutic donor lymphocyte infusion to prevent or treat leukemia relapse afte…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study [NA]
Completed clinical trial evaluating a geriatric optimization plan to improve survival in older adults undergoing allogeneic hematopoietic ce…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Open-label Phase 1b/II trial evaluating Glofitamab in combination with Atezolizumab or Polatuzumab Vedotin in adults with relapsed/refractor…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies [Phase 2]
Phase 2 clinical trial evaluating MT2021-08T, a T-cell receptor alpha/beta-depleted donor peripheral blood stem cell product, for hematologi…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma [Phase 1, Phase 2]
A phase 1/2 dose-escalation trial evaluating glofitamab as a single agent and in combination with obinutuzumab after a fixed pre-treatment d…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports on AB-101 as a monotherapy and in combination with immunotherapy for relapsed/refractory B-cell Non-Hodgk…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: 9-ING-41 in Patients With Advanced Cancers [Phase 2]
Actuate Therapeutics' Phase 2 trial of 9-ING-41 in patients with advanced cancers is currently active but not recruiting, with pancreatic ca…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-c…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
A multicenter clinical trial is evaluating how social and genetic factors influence outcomes among adolescent and young adult survivors of H…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
Clinical trial update for Allo-QuadCAR01-T, an allogeneic CD19/CD20 CAR-T, in relapsed or refractory B-cell malignancies, currently recruiti…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial of tazemetostat plus venetoclax for relapsed/refractory non-Hodgkin lymphoma has been terminated, including diffuse l…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer [Phase 2]
TAPUR is a Phase 2 study testing FDA-approved cancer drugs that target specific tumor gene abnormalities in patients with advanced cancers; …
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination wit…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating a therapy for relapsed or refractory non-Hodgkin lymphoma is currently recruiting. Sponsored by Immunity…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma [Phase 1]
A Phase 1 study evaluating therapy for relapsed/refractory Non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies [Phase 1, Phase 2]
Phase 1/2 trial update for SHB-02-CD19, a novel CD19-directed CAR-T therapy, in CD19-expressing B-cell malignancies; recruitment not yet sta…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating memory-enriched T cells following stem cell transplantation for recurrent B-cell non-Hodgkin lymphomas; the study i…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL [Phase 2]
Phase 2 single-arm trial evaluating ablative bridging irradiation before CD19 CAR-T therapy in high-risk relapsed/refractory large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency [NA]
A completed clinical trial evaluated cholecalciferol (vitamin D3) in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma who …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) [Phase 2, Phase 3]
Clinical trial update for NexCAR19 (Talikabtagene autoleucel), a CAR-T therapy studied in relapsed/refractory B-cell malignancies; the Phase…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma [NA]
Clinical trial update for LIBERTY, a study using liquid biopsy to diagnose and monitor CNS involvement in high-risk B-cell non-Hodgkin lymph…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers [Phase 1]
Phase 1 trial update for IOA-244, a PI3Kδ inhibitor, being studied in metastatic cancers with status currently ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating carmustine with and without ethanol in subjects with lymphoma, including Hodgkin and non-Hodgkin lymphom…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant [Phase 1]
Phase 1 clinical trial evaluating CMV-MVA Triplex Vaccine to enhance CMV-specific immunity and prevent CMV viremia in patients undergoing ha…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) [Phase 2]
The CAPTUR Phase 2 trial by the Canadian Cancer Trials Group is currently recruiting and evaluates profiling and targeted agent utilization …